NIPH Clinical Trials Search

Zinc supplementation for patients with acute myocardial infarction

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	Acute myocardial infarction
Date of first enrollment	2017/12/02
Target sample size	52
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Zinc acetate 25 mg twice dairy, 3 days Conventional therapy Conventional therapy

Outcome(s)

Primary Outcome	Length of stay in the coronary care unit Length of hospitalization stay Infarct size, LVEF evaluated by MRI
Secondary Outcome	The rate of requiring specific ancillary devices such as a temporary pacemaker, intra-aortic balloon pump (IABP), invasive and non-invasive positive pressure ventilation or venoarterial extracorporeal membrane oxygenation (VA-ECMO) LVEF, serum CK, CK-MB,BNP level all-cause and cardiovascular mortality

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	(1)Hepatic cirrhosis (2)Dialysis (3)Inflammatory bowel disease (4)Chronic pancreatitis (5)After enterectomy or pancreaticoduodenectomy (6)Systemic inflammatory disease (7)Sickle cell anemia (8)Asthma, allergy of Gadolinium, MRI-none compatible pacemaker implanted (9)allergy of Zinc acetate (10) Patients with CTO in non-infarct related artery